Progress in the treatment of NK-cell lymphoma/leukemia

Abstract

Natural killer (NK)/T cell lymphoma includes two major subtypes of disease, specifically extranodal NK/T cell lymphoma, nasal type (ENKL) and aggressive NK cell leukemia (ANKL). Both are strongly associated with Epstein-Barr virus and are prevalent in East Asia and Latin America. Except for that of limited-stage ENKL, the prognosis of both diseases was poor in the previous decade. The advent of non-anthracycline-based chemoradiotherapy has contributed to an improvement in ENKL prognosis, but there is still room for further treatment progress. Recently, the high efficacy of PD-1 antibody was reported in relapsed or refractory ENKL patients. This was later supported by the finding that PD-L1/PD-L2 genetic alterations are frequently observed in ENKL and ANKL patients. Due to the rarity of the disease, a standard treatment for ANKL remains to be established. Currently, allogeneic stem cell transplantation is the only curative treatment, and this is even applicable to chemo-resistant ANKL patients. In this review, we focus on recent treatment approaches for NK/T cell lymphomas including novel agents.

Keywords

Extranodal NK/T-cell lymphoma / nasal type / aggressive NK-cell leukemia / Epstein-Barr virus / hematopoietic stem cell transplantation / L-asparaginase

References

[1] Campo E,Jaffe ES. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO Press; 2008.

[2] Lymphoma Study Group of Japanese PathologistsThe world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities.Pathol Int2000;50:696-702

[3] Bassig BA,Mang O.Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010.Cancer Epidemiol2016;42:15-23

[4] Sun J,Lu Z.Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification.Am J Clin Pathol2012;138:429-34

[5] Suzuki R,Yamaguchi M.NK-cell Tumor Study GroupPrognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.Ann Oncol2010;21:1032-40

[6] Au WY,Intragumtornchai T.International Peripheral T-Cell Lymphoma ProjectClinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.Blood2009;113:3931-7

[7] Yamaguchi M,Oguchi M.Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan.J Clin Oncol2017;35:32-9

[8] Fox CP,Ko Y.Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.Lancet Haematol2020;7:e284-94

[9] Pongpruttipan T,Assanasen T.Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study.Am J Surg Pathol2012;36:481-99

[10] Fernandez LA,Lee C.Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.Blood1986;67:925-30

[11] Suzuki R,Nakamura S.NK-cell Tumor Study GroupAggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells.Leukemia2004;18:763-70

[12] Ishida F,Kim WS.Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.Cancer Sci2012;103:1079-83 PMCID:PMC7685073

[13] Kimura H,Kawabe S.EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.Blood2012;119:673-86

[14] Ko YH,Kim K,Kim WS.Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis?.Acta Haematol2008;120:199-206

[15] Nicolae A,Pham TH.EBV-negative aggressive NK-cell leukemia/lymphoma: clinical, pathologic, and genetic features.Am J Surg Pathol2017;41:67-74 PMCID:PMC5159195

[16] Suzuki R.NK/T Cell Lymphoma: updates in therapy.Curr Hematol Malig Rep2018;13:7-12

[17] Yang Y,Liu X.Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.Leukemia2021;35:1671-82 PMCID:PMC8179849

[18] Kim SJ,Jaccard A.A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.Lancet Oncol2016;17:389-400

[19] Lee J,Park YH.Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.J Clin Oncol2006;24:612-8

[20] Suzuki R,Oshimi K.Differences between nasal and extranasal NK/T-cell lymphoma.Blood2009;113:6260-1; author reply 6261-2

[21] Tang YT,Luo H.Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.Blood Cancer J2017;7:660 PMCID:PMC5802497

[22] Li YX,Jin J.Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma.J Clin Oncol2006;24:181-9

[23] Vargo JA,Glaser SM.The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.Cancer2017;123:3176-85

[24] Cheung MM,Lau WH.Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.J Clin Oncol1998;16:70-7

[25] Kim GE,Yang WI.Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment.J Clin Oncol2000;18:54-63

[26] Koom WS,Yang WI.Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints.Int J Radiat Oncol Biol Phys2004;59:1127-37

[27] Yang CW,Hong RL.Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.J Radiat Res2017;58:114-22 PMCID:PMC5321187

[28] Yang Y,Cao JZ.Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.Blood2015;126:1424-32; quiz 1517

[29] Miller TP,Cassady JR.Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.N Engl J Med1998;339:21-6

[30] Egashira M,Sugimoto K.P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.Blood1999;93:599-606

[31] Yamaguchi M,Miwa H.Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.Cancer1995;76:2351-6

[32] Ribrag V,Janot F.Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx.Leukemia2001;15:1123-6

[33] Ribrag V,Janot F.Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx.Leukemia2001;15:1123-6

[34] You JY,Yang MH.Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan.Ann Oncol2004;15:618-25

[35] Wang B,Ma X.Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.Leuk Lymphoma2007;48:396-402

[36] Yamaguchi M,Oguchi M.Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.J Clin Oncol2009;27:5594-600

[37] Kim SJ,Kim BS.Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study.J Clin Oncol2009;27:6027-32

[38] Kim SJ,Kim JS.Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.Ann Hematol2014;93:1895-901

[39] Ando M,Kitoh T.Selective apoptosis of natural killer-cell tumours by l-asparaginase.Br J Haematol2005;130:860-8

[40] Chen JS,Lin DT,Jou ST.Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens.Br J Haematol1998;103:756-62

[41] Uno M,Moriwaki A.In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A.Br J Haematol2001;113:1009-14

[42] Yamaguchi M,Kim WS.Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.J Clin Oncol2011;29:4410-6

[43] Kwong YL,Tse E.Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.Ann Oncol2018;29:256-63

[44] Liang R,Chan TK.Treatment outcome and prognostic factors for primary nasal lymphoma.J Clin Oncol1995;13:666-70

[45] Nagafuji K,Arima F.L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.Int J Hematol2001;74:447-50

[46] Matsumoto Y,Kanda-Akano Y.Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.Leuk Lymphoma2003;44:879-82

[47] Obama K,Niina K.L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma.Int J Hematol2003;78:248-50

[48] Yong W,Zhang Y.L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.Int J Hematol2003;78:163-7

[49] Jaccard A,Girault S.L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.Ann Oncol2009;20:110-6

[50] Qi S,Hsu M.Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.Leuk Lymphoma2016;57:2575-83 PMCID:PMC5592793

[51] Wang JH,Liu CC.Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.Oncotarget2016;7:29092-101 PMCID:PMC5045380

[52] Horwitz SM,Ai WZ.NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.J Natl Compr Canc Netw2018;16:123-35

[53] Jaccard A,Marin B.GELA and GOELAMS IntergroupEfficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.Blood2011;117:1834-9

[54] Jaccard A,Delmer A.A prospective phase II trial of an L-asparaginase containing regimen in extra nodal NK/T-cell lymphoma.Hematol Oncol2013;31:129

[55] Li X,Sun Z.DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China.Clin Cancer Res2016;22:5223-8

[56] Yhim HY,Mun YC.Consortium for Improving Survival of Lymphoma StudyClinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma.Biol Blood Marrow Transplant2015;21:1597-604

[57] Kharfan-Dabaja MA,Ayala E.Clinical Practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an International Collaborative Effort on Behalf of The Guidelines Committee of The American Society for blood and marrow transplantation.Biol Blood Marrow Transplant2017;23:1826-38

[58] Song GY,Suh C.Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.Bone Marrow Transplant2021;56:1205-8 PMCID:PMC8113056

[59] Kim H,Yamaguchi M.Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.Blood2020;136:2548-56

[60] Kanate AS,Ahn KW.Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.Br J Haematol2018;182:916-20 PMCID:PMC5796874

[61] Jung KS,Kim SJ,Kang ES.L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.J Hematol Oncol2016;9:41 PMCID:PMC4835915

[62] Takahashi H,Hattori Y.Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure.Leuk Lymphoma2013;54:662-4

[63] Teshima T,Fukuda M.Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia.Lancet1996;347:1124

[64] Murashige N,Kishi Y.Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.Br J Haematol2005;130:561-7

[65] Ito T,Nakazawa H.Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation.Eur J Haematol2008;81:107-11

[66] Hamadani M,DiGilio A.Allogeneic hematopoietic cell transplantation for aggressive NK cell leukemia. A center for international blood and marrow transplant research analysis.Biol Blood Marrow Transplant2017;23:853-6 PMCID:PMC5410937

[67] Jeong SH,Park JS.Allogeneic stem cell transplantation for patients with natural killer/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation.Biol Blood Marrow Transplant2018;24:2471-8

[68] Fujimoto A,Izutsu K.Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.Bone Marrow Transplant2021;56:347-56

[69] Chen BJ,Ouyang J.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.Clin Cancer Res2013;19:3462-73 PMCID:PMC4102335

[70] Kataoka K,Sakata S.Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.Leukemia2019;33:1687-99 PMCID:PMC6755969

[71] Kwong YL,Tan D.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.Blood2017;129:2437-42

[72] Lim JQ,Tang T.Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.Leukemia2020;34:3413-9 PMCID:PMC7685978

[73] Li X,Zhang M.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.J Hematol Oncol2018;11:15 PMCID:PMC5793390

[74] Chan TSY,Loong F,Tse E.PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.Ann Hematol2018;97:193-6

[75] Li J,Fan L.Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).J Clin Oncol2020;38:8050

[76] Kim SJ,Laurensia Y.Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.Blood2020;136:2754-63

[77] Gao Y,Wang X.Anti-PD-1 antibody (Sintilimab) plus histone deacetylase inhibitor (Chidamide) for the treatment of refractory or relapsed extranodal natural killer/T cell lymphoma, nasal type (r/r-ENKTL): preliminary results from a prospective, multicenter, single-arm, phase Ib/II trial (SCENT).Blood2020;136:39-40

[78] Cai J,Huang H.Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.Signal Transduct Target Ther2020;5:289 PMCID:PMC7772337

[79] Du L,Li L.Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for relapsed/refractory natural killer/T-cell lymphoma: a report of three cases.Onco Targets Ther2020;13:7189-97 PMCID:PMC7394590

[80] Kim HK,Moon JH,Byeon S.Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.Blood Res2015;50:254-6 PMCID:PMC4705052

[81] Poon LM.Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.Ann Hematol2016;95:847-9

[82] Kim SJ,Kim JS.Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial.Cancer Res Treat2020;52:374-87 PMCID:PMC7176958

[83] Hari P,Olteanu H.Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma.N Engl J Med2016;375:1501-2

[84] Huang H-q,Yao M.Daratumumab monotherapy for patients with relapsed or refractory (R/R) natural killer/T-cell lymphoma (NKTCL), nasal type: updated results from an open-label, single-arm, multicenter phase 2 study.Blood2019;134:1568

[85] Shi Y,Hong X.Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.Ann Oncol2015;26:1766-71

[86] Fujimoto A.Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes.Cancers (Basel)2020;12:328 PMCID:PMC7072403

[87] Bollard CM,Torrano V.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.J Clin Oncol2014;32:798-808 PMCID:PMC3940538

[88] Cho SG,Sohn HJ.Long-term outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs.Mol Ther2015;23:1401-9 PMCID:PMC4817864

[89] Huang Y,de Leval L.Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type.Blood2010;115:1226-37 PMCID:PMC2826234

[90] Lee S,Kang SY.Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.Oncotarget2015;6:17764-76 PMCID:PMC4627344

[91] Küçük C,Hu X.Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Nat Commun2015;6:6025

[92] Nairismägi ML,Li ZM.Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.Leukemia2018;32:1147-56 PMCID:PMC5940653

[93] Koo GC,Tang T.Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.Cancer Discov2012;2:591-7

[94] Sim SH,Kim TM.Novel JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal type.Am J Pathol2017;187:980-6

[95] Dufva O,Kelkka T.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Nat Commun2018;9:1567 PMCID:PMC5908809